<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03016988</url>
  </required_header>
  <id_info>
    <org_study_id>Fujian Medical University</org_study_id>
    <nct_id>NCT03016988</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma</brief_title>
  <official_title>Bortezomib Combined With Fludarabine and Cytarabine for Mantle Cell Lymphoma Patients：a Single Arm, Open-labelled, Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tingbo Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Union hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL) and shows poor survival.
      This study to evaluate the efficacy and safety of Bortezomib combined with Fludarabine and
      Cytarabine treatment in the naive and relapsed MCL who are not eligible for high dose therapy
      and transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The eligibility criteria were pathologically confirmed, previously untreated MCL or relapsed
      MCL as defined by the World Health Organization classification; age≥18 years; Eastern
      Cooperative Oncology Group (ECOG) performance status of 0-2; adequate haematologic function
      (haemoglobin &gt; 9.0 g/l, absolute neutrophil count &gt; 1500/ml, platelets &gt; 75,000/l), hepatic
      function (total serum bilirubin ≤ 1.5 times the upper limit of normal, alanine
      aminotransferase and aspartate aminotransferase ≤ 2.5 times the upper limit of normal), renal
      function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50 ml/min); normal coagulation
      function and electrocardiogram results. Stage was defined according to the Ann Arbor system.

      The Fujian Medical University Union Hospital approved this study before subjects were
      enrolled.

      Treatment dosages were as follows:

      days 1,4,8,and 11 subcutaneous infusion of 1.3mg/m2 Bortezomib. Days 1-3 intravenous infusion
      25mg/m2 Fludarabine. Days 1-3 intravenous infusion of 500mg/m2 Cytarabine. The regimen was
      repeated every 28 days for a maximum of six cycles.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>Follow-up to 36 months</time_frame>
    <description>Interval from registration to progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Lugano classification</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bortezomib,Fludarabine and Cytarabine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11; Fludarabine(F) 25mg/m2, intravenously day 1-3; Cytarabine(A) 500mg/m2 for 3 days(day1-3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;</description>
    <arm_group_label>Bortezomib,Fludarabine and Cytarabine</arm_group_label>
    <other_name>Bortezomib (PS-341)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine(F) 25mg/m2, intravenously day 1-3;</description>
    <arm_group_label>Bortezomib,Fludarabine and Cytarabine</arm_group_label>
    <other_name>NSC 118218</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine(A) 500mg/m2 for 3 days(day1-3)</description>
    <arm_group_label>Bortezomib,Fludarabine and Cytarabine</arm_group_label>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria:

          1. pathologically confirmed, previously untreated MCL or relapsed MCL as defined by the
             World Health Organization classification;

          2. age≥18 years;

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

          4. adequate haematologic function (haemoglobin &gt; 9.0 g/l, absolute neutrophil count &gt;
             1500/ml, platelets &gt; 75,000/l),

          5. adequate hepatic function (total serum bilirubin ≤ 1.5 times the upper limit of
             normal, alanine aminotransferase and aspartate aminotransferase ≤ 2.5 times the upper
             limit of normal),

          6. adequate renal function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50
             ml/min);

          7. normal coagulation function and electrocardiogram results.

          8. willingness to provide written informed consent.

        Exclusion Criteria:

          1. MCL patients who do NOT response or are refractory to preview treatment.

          2. Who do NOT sign the consent form.

          3. whose life expectation is less than 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://jco.ascopubs.org/content/34/11/1256.long</url>
    <description>test link</description>
  </link>
  <results_reference>
    <citation>Cheah CY, Seymour JF, Wang ML. Mantle Cell Lymphoma. J Clin Oncol. 2016 Apr 10;34(11):1256-69. doi: 10.1200/JCO.2015.63.5904. Epub 2016 Jan 11. Review.</citation>
    <PMID>26755518</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>January 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Tingbo Liu</investigator_full_name>
    <investigator_title>Professor of medicine</investigator_title>
  </responsible_party>
  <keyword>Mantle cell lymphoma</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Cytarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

